Insider Transactions in Q1 2024 at G1 Therapeutics, Inc. (GTHX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 20
2024
|
Monica R. Thomas Chief Legal & People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+24.49%
|
-
|
|
Mar 20
2024
|
John V. Umstead Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+18.85%
|
-
|
|
Mar 20
2024
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+31.46%
|
-
|
|
Mar 18
2024
|
John V. Umstead Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,547
-5.02%
|
$19,641
$3.02 P/Share
|
|
Feb 12
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
28,600
-14.41%
|
$114,400
$4.62 P/Share
|
|
Feb 12
2024
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,600
+12.59%
|
$0
$0.3 P/Share
|
|
Jan 04
2024
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
721
-0.69%
|
$1,442
$2.94 P/Share
|
|
Jan 04
2024
|
Mark Avagliano Chief Business Officer |
SELL
Open market or private sale
|
Direct |
721
-0.61%
|
$1,442
$2.94 P/Share
|
|
Jan 04
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
721
-0.42%
|
$1,442
$2.94 P/Share
|
|
Jan 04
2024
|
John V. Umstead Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
111
-0.09%
|
$222
$2.94 P/Share
|
|
Jan 03
2024
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,019
-1.41%
|
$9,057
$3.12 P/Share
|
|
Jan 03
2024
|
Terry L Murdock Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,300
+25.78%
|
-
|
|
Jan 03
2024
|
Mark Avagliano Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,360
-1.38%
|
$10,080
$3.12 P/Share
|
|
Jan 03
2024
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,760
+26.85%
|
-
|
|
Jan 03
2024
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
11,686
-1.17%
|
$35,058
$3.12 P/Share
|
|
Jan 03
2024
|
John E. (Jack) Bailey Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
100,700
+16.73%
|
-
|
|
Jan 03
2024
|
Andrew Perry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,413
-1.35%
|
$7,239
$3.12 P/Share
|
|
Jan 03
2024
|
Andrew Perry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,570
+27.27%
|
-
|
|
Jan 03
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,019
-0.87%
|
$9,057
$3.12 P/Share
|
|
Jan 03
2024
|
Rajesh Malik Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,300
+17.68%
|
-
|
|
Jan 03
2024
|
Monica R. Thomas Chief Legal & People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,975
+26.36%
|
-
|
|
Jan 03
2024
|
John V. Umstead Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
632
-0.24%
|
$1,896
$3.12 P/Share
|
|
Jan 03
2024
|
John V. Umstead Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,300
+22.14%
|
-
|
|
Jan 02
2024
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
32,983
-7.61%
|
$98,949
$3.27 P/Share
|